Hong, J., Sui, P., Li, Y., Xu, K. Y., Lee, J.-H., Wang, J., Chen, S., Zhang, P., Wingate, N., Noor, A., Yuan, Y., Hromas, R., Zhou, H., Hamamoto, K., Su, R., Yin, C. C., Ye, F., Quesada, A. E., Chen, J., … Xu, M. (2025). PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell Stem Cell. https://doi.org/10.1016/j.stem.2025.01.010

Zarco, N., Dovas, A., de Araujo Farias, V., Nagaiah, N. K. H., Haddock, A., Sims, P. A., Hambardzumyan, D., Meyer, C. T., Canoll, P., Rosenfeld, S. S., & Kenchappa, R. S. (2024). Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. IScience, 27(12), 111311. https://doi.org/10.1016/j.isci.2024.111311

Maynard, R., Fitzgerald, A., Nasir, A., Eisman, S. E., Jablonski, S. A., Pearson, G., Mace, E., & Weiner, L. M. (2024). 1123 Promoting immune cell tumor invasion through forced overexpression of proteases. Regular and Young Investigator Award Abstracts, A1245–A1245. https://doi.org/10.1136/jitc-2024-sitc2024.1123

Kumbier, K., Roth, M., Li, Z., Lazzari-Dean, J., Waters, C., Hammerlindl, S., Rinaldi, C., Huang, P., Korobeynikov, V. A., Phatnani, H., Shneider, N., Jacobson, M. P., Wu, L. F., & Altschuler, S. J. (2024). Identifying FUS amyotrophic lateral sclerosis disease signatures in patient dermal fibroblasts. Developmental Cell. https://doi.org/10.1016/j.devcel.2024.05.011

Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P., Mahajan, A., Humala, N., Manier, L., Caprioli, R., Quiñones-Hinojosa, A., Casaccia, P., & Canoll, P. (2024). EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. Cells, 13(3), 219. https://doi.org/10.3390/cells13030219

Verma, A., Chi, Y.-Y., Malvar, J., Lamble, A., Chaudhury, S., Agarwal, A., Li, H.-T., Liang, G., Leong, R., Brown, P. A., Kaplan, J., Schafer, E. S., Slone, T., Pauly, M., Chang, B. H., Stieglitz, E., Wayne, A. S., Hijiya, N., & Bhojwani, D. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers, 16(3), 496. https://doi.org/10.3390/cancers16030496

Karagiannis, D., Wu, W., Li, A., Hayashi, M., Chen, X., Yip, M., Mangipudy, V., Xu, X., Sánchez-Rivera, F. J., Soto-Feliciano, Y. M., Ye, J., Papagiannakopoulos, T., & Lu, C. (2024). Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors. Cell Reports, 43(1), 113629. https://doi.org/10.1016/j.celrep.2023.113629

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 4316–4316. https://doi.org/10.1182/blood-2023-186376

Piorczynski, T. B., Ryu, Y. K., Pazos, M., Huang, W., Tolu, S. S., Estrella, B., & Amengual, J. E. (2023). Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 4391–4391. https://doi.org/10.1182/blood-2023-179271

Bernard, E., Hasserjian, R., Greenberg, P. L., Arango Ossa, J. E., Creignou, M., Nannya, Y., Tuechler, H., Medina-Martínez, J. S., Levine, M. F., Jädersten, M., Germing, U., Sanz, G., van de Loosdrecht, A. A., Kosmider, O., Follo, M. Y., Thol, F., Zamora, L., Pinheiro, R. F., Pellagatti, A., … Papaemmanuil, E. (2023). Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications. Blood, 142(Supplement 1), 997–997. https://doi.org/10.1182/blood-2023-186863

Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Larson, J. D., Wechsler-Reya, R. J., Sirianni, R. W., & Elmquist, W. F. (2023). Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors. Journal of Pharmacology and Experimental Therapeutics, 387(3), 315–327. https://doi.org/10.1124/jpet.123.001826

Li, A. M., He, B., Karagiannis, D., Li, Y., Jiang, H., Srinivasan, P., Ramirez, Y., Zhou, M.-N., Curtis, C., Gruber, J. J., Lu, C., Rankin, E. B., & Ye, J. (2023). Serine starvation silences estrogen receptor signaling through histone hypoacetylation. Proceedings of the National Academy of Sciences, 120(38). https://doi.org/10.1073/pnas.2302489120

Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., & O’Connor, O. A. (2023). Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma. Hematological Oncology, 41(S2), 313–314. Portico. https://doi.org/10.1002/hon.3164_220

Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., & Piekarz, R. (2023). ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. Hematological Oncology, 41(S2), 833–834. Portico. https://doi.org/10.1002/hon.3166_ot14

Labella, R., Ali, A., Mosialou, I., De Angelis, J., Vgenopoulou, P., Zhao, J., Vanderberg, A., Rabadan, R., Raza, A., & Kousteni, S. (2023). 2013 – MESENCHYMAL STROMAL CELL MITOCHONDRIAL TRANSFER FUELS MDS TO AML TRANSFORMATION. Experimental Hematology, 124, S43. https://doi.org/10.1016/j.exphem.2023.06.050

Estrella, B., Pazos, M. A., Ricker, E. C., Ryu, Y. K., Piorczynski, T. B., Liu, Y., Tolu, S., & Amengual, J. E. (2022). First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade. Blood, 140(Supplement 1), 358–359. https://doi.org/10.1182/blood-2022-166929

Zhou, D., Wu, Z., Park, J.-G., Fiches, G. N., Li, T.-W., Ma, Q., Huang, H., Biswas, A., Martinez-Sobrido, L., Santoso, N. G., & Zhu, J. (2022). FACT subunit SUPT16H associates with BRD4 and contributes to silencing of interferon signaling. Nucleic Acids Research, 50(15), 8700–8718. https://doi.org/10.1093/nar/gkac645

Martínez-Hernández, J., Parato, J., Sharma, A., Soleilhac, J.-M., Qu, X., Tein, E., Sproul, A., Andrieux, A., Goldberg, Y., Moutin, M.-J., Bartolini, F., & Peris, L. (2022). Crosstalk between acetylation and the tyrosination/detyrosination cycle of α-tubulin in Alzheimer’s disease. Frontiers in Cell and Developmental Biology, 10. https://doi.org/10.3389/fcell.2022.926914

Basseville, A., Violet, P.-C., Safari, M., Sourbier, C., Linehan, W. M., Robey, R. W., Levine, M., Sackett, D. L., & Bates, S. E. (2022). A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 14(11), 2643. https://doi.org/10.3390/cancers14112643

Zacharoulis, S., Szalontay, L., CreveCoeur, T., Neira, J., Higgins, D., Englander, Z., Spinazzi, E., Sethi, C., Canoll, P., Garvin, J., Zylber, R., Damment, S., Zamoryakhin, D., Maddocks, A., Feldstein, N., & Bruce, J. (2022). DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Neuro-Oncology, 24(Supplement_1), i35–i35. https://doi.org/10.1093/neuonc/noac079.128

Nguyen, T. T. T., Shang, E., Schiffgens, S., Torrini, C., Shu, C., Akman, H. O., Prabhu, V. V., Allen, J. E., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2022). Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical Cancer Research, 28(9), 1881–1895. https://doi.org/10.1158/1078-0432.ccr-21-2857